Experienced in Riboflavin Transporter Deficiency Neuronopathy

Dr. Craig Zaidman

Neurology
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Craig Zaidman is a Neurologist in Saint Louis, Missouri. Dr. Zaidman is rated as an Experienced provider by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis.

His clinical research consists of co-authoring 78 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Riboflavin Transporter Deficiency Neuronopathy.

Specialties
Neurology
Licenses
Neurology with Special Qualifications in Neurology in MO
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Washington University
660 S Euclid Ave, Saint Louis, MO 63110
Other Locations
Office
1 Childrens Pl Ste 2D, Saint Louis,, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Enrollment Status: Recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: January 26, 2026
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: January 26, 2026
Intervention Type: Biological
Study Phase: Phase 1
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Genetic
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
View 7 Less Clinical Trials

77 Total Publications

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy.
Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy.
Journal: Neuromuscular disorders : NMD
Published: June 17, 2025
Similar Doctors
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Paul T. Golumbek
Neurology | Pediatric Neurology
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Paul T. Golumbek
Neurology | Pediatric Neurology
4921 Parkview Pl Ste 6c, Ste 6c, 
Saint Louis, MO 
 (0.3 miles away)
314-362-4838
Languages Spoken:
English

Paul Golumbek is a Neurologist and a Pediatric Neurologist in Saint Louis, Missouri. Dr. Golumbek is rated as an Experienced provider by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Primary Lateral Sclerosis, Riboflavin Transporter Deficiency Neuronopathy, Becker Muscular Dystrophy, and Duchenne Muscular Dystrophy.

Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Timothy M. Miller
Neurology
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Timothy M. Miller
Neurology

Washington University

4921 Parkview Pl, Suite 6c, 
Saint Louis, MO 
 (0.2 miles away)
314-362-1408
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Timothy Miller is a Neurologist in Saint Louis, Missouri. Dr. Miller is rated as an Advanced provider by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Spinal and Bulbar Muscular Atrophy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy Type 3, and Spinal Muscular Atrophy (SMA). Dr. Miller is currently accepting new patients.

Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Robert P. Margolis
Neurology
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Robert P. Margolis
Neurology

Ssm Medical Group Inc

12266 De Paul Dr, Suite 100, 
Bridgeton, MO 
 (12.2 miles away)
314-738-2770
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients

Robert Margolis is a Neurologist in Bridgeton, Missouri. Dr. Margolis is rated as a Distinguished provider by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Foot Drop, Essential Tremor, Corticobasal Degeneration, and Cerebellar Degeneration. Dr. Margolis is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zaidman's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile